



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Michael John Reed et al.  
Serial No. : 10/084,235  
For : STEROID SULPHATASE INHIBITORS  
Filed : February 25, 2002  
Examiner : Badio, Barbara P.  
Art Unit : 1616


745 Fifth Avenue, New York, NY 10151  
**EXPEDITED PROCEDURE**  
**RESPONSE AFTER FINAL ACTION**  
**UNDER 37 C.F.R. §1.116**


**EXPRESS MAIL**

Mailing Label Number: EV 7233690305 US

Date of Deposit: September 1, 2005

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: **Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

  
(Typed or printed name of person mailing paper or fee)

  
(Signature of person mailing paper or fee)

**COMMUNICATION**

MAIL STOP AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed are certified copies of four priority documents for the above named application.

Applicants hereby claim priority under 35 U.S.C. §§119 from the following applications:

GB9604709.7 filed March 5, 1996;  
GB9605725.2 filed March 19, 1996;  
GB9603325.3 filed February 16, 1996; and,  
GB9625334.9 filed December 5, 1996.

Acknowledgment of the claim of priority and receipt of the certified copies is requested.

FROMMER LAWRENCE & HAUG LLP  
Attorneys for Applicants

By: Thomas J. Kowalski by Angela M. Collison  
Thomas J. Kowalski  
Reg. No. 32,147  
Angela M. Collison  
Reg. No. 51,107  
(212) 588-0800



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit den in  
den Akten befindlichen  
Unterlagen der unten be-  
zeichneten europäischen  
Patentanmeldung überein  
(Regel 94(4) EPU).

The attached is a true copy  
of documents contained in  
the European patent appli-  
cation indicated below  
(Rule 94(4) EPC).

Les documents ci-annexés  
sont conformes aux  
documents figurant dans  
le dossier de la demande  
de brevet dont le numéro  
est indiqué ci-dessous  
(règle 94(4) CBE).

Patentanmeldung Nr. Patent application No. Demande de brevet n°

97905332.9

CERTIFIED COPY OF  
PRIORITY DOCUMENT



München, den  
Munich,  
Munich, le

27/07/05

Der Präsident des Europäischen Patentamts;  
Im Auftrag.

For the President of the European Patent Office.

Président de l'Office européen des brevets

D.M. Furst-Fontaine

BEST AVAILABLE COPY

9790 5332-9



The  
Patent  
Office

PCT/GB 97/00600 (1)

The Patent Office  
Cardiff Road  
Newport  
Gwent  
NP9 1RH

REC'D 03 APR 1997

WIPO

FCI

he undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

18.3.1997

PRIORITY DOCUMENT

# Patents Form 1/77


Patents Act 1977  
(Rule 16)

The  
Patent  
Office



## Request for a grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



RECEIVED BY HAND  
5 MAR 1996

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Our reference

N 697 8 CTH

**9604709.7**

2. Patent application number

(The Patent Office will fill in this part)

3. Full name, address and postcode of the or of each applicant  
(underline all surnames)

IMPERIAL COLLEGE OF SCIENCE  
TECHNOLOGY AND MEDICINE  
SHERFIELD BUILDING  
EXHIBITION ROAD  
LONDON  
SW7 2AZ  
UNITED KINGDOM

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation UNITED KINGDOM

6061469001

4. Title of the invention

A COMPOUND

5. Name of your agent (if you have one)

D YOUNG & CO

"Address for service" in the United Kingdom to which all correspondence should be sent  
(including the postcode)

21 NEW FETTER LANE  
LONDON  
EC4A 1DA

Patents ADP number (if you have one)

59006

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country

Priority application  
number  
(if you know it)

Date of filing  
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application

Number of earlier  
application

Date of filing  
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d)) YES

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form NONE

Description 17

Claims(s) 5

Abstract 1

Drawing(s) 5

10. If you are also filing any of the following, state how many against each item.

Priority documents NONE

Translations of priority documents NONE

Statement of inventorship and right to grant of a patent (Patents Form 7/77) NONE

Request for preliminary examination and search (Patents Form 9/77) NONE

Request for substantive examination (Patents Form 10/77) NONE

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*D Young & Co*

05 03 96

D YOUNG & CO

Agents for the Applicants

12. Name and daytime telephone number of the person to contact in the United Kingdom

DR CHARLES HARDING

01703 634816

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505

b) Write your answers in capital letters using black ink or you may type them

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patent Office.

## A COMPOUND

The present invention relates to a compound.

5 In particular the present invention relates to a pharmaceutical composition comprising the compound.

Breast and endometrial cancers are major causes of death in Western women. In particular, tumours in endocrine-dependent tissues, such as the breast and  
10 endometrium, occur most frequently in postmenopausal women at a time when the ovaries have ceased their production of oestrogens.

Evidence suggests that oestrogens are the major mitogens involved in stimulating and promoting the growth of tumours in endocrine-dependent tissues, such as the breast  
15 and endometrium<sup>21</sup>. Although plasma oestrogen concentrations are similar in women with ~~or~~ without breast cancer, ~~breast tumour oestrone and oestradiol levels~~ are significantly higher than in normal breast tissue or blood. In addition, in postmenopausal women oestrogens continue to be produced by extraglandular production in adipose tissue but also in normal and malignant breast tissues<sup>22</sup>.

20 Figures 1 and 2 are schematic diagrams showing some of the enzymes involved in the *in situ* synthesis of oestrone from oestrone sulphate, oestradiol and androstenedione.

In Figure 2, which schematically shows the origin of oestrogenic steroids in  
25 postmenopausal women, "ER" denotes Oestrogen Receptor, "DHA/-S" denotes Dehydroepiandrosterone/-Sulphate, "Adiol" denotes Androstenediol, "E1-STS" denotes Oestrone Sulphatase, "DHA-STS" denotes DHA-sulphatase, "Adiol-STS" denotes Adiol Sulphatase, and "17B-HSD" denotes Oestradiol 17B-hydroxysteroid dehydrogenase.

30 As can be seen, the main two enzymes that are involved in the peripheral synthesis of oestrogens are the aromatase enzyme and the enzyme oestrone sulphatase.

In short, the aromatase enzyme converts androstenedione, which is secreted in large amounts by the adrenal cortex, to oestrone. Recent reports have suggested that some flavones could inhibit aromatase activity<sup>35,36</sup>.

5 Much of the oestrone so formed, however, is converted to oestrone sulphate (E1S) and there is now a considerable body of evidence showing that E1S in plasma and tissue acts as a reservoir for the formation of oestrone by the action of oestrone sulphatase<sup>23</sup>.

10 In this regard, it is now believed that the oestrone sulphatase (E1-STS) pathway - i.e. the hydrolysis of oestrone sulphate to oestrone (E1S to E1) is the major source of oestrogen in breast tumours<sup>1,2</sup>. This theory is supported by a modest reduction of plasma oestrogen concentration in postmenopausal women with breast cancer treated by aromatase inhibitors, such as aminoglutethimide and 4-hydroxyandrostenedione<sup>3,4</sup>  
15 and also by the fact that plasma E1S concentration in these aromatase inhibitor-treated patients remains relatively high. ~~The long half-life of E1S in blood (10-12 h)~~ compared with the unconjugated oestrogens (20 min)<sup>5</sup> and high levels of steroid sulphatase activity in liver and, normal and malignant breast tissues, also lend support to this theory<sup>6</sup>.

20

Thus, oestrogen formation in malignant breast and endometrial tissues *via* the sulphatase pathway makes a major contribution to the high concentration of oestrogens which are present in these tumours<sup>24,25</sup>.

25 PCT/GB92/01587 teaches novel steroid sulphatase inhibitors and pharmaceutical compositions containing them for use in the treatment of oestrone dependent tumours, especially breast cancer. These steroid sulphatase inhibitors are sulphamate esters, such as N,N-dimethyl oestrone-3-sulphamate and, preferably, oestrone-3-sulphamate (otherwise known as "EMATE").

30



EMATE is a potent E1-STS inhibitor as it displays more than 99% inhibition of E1-STS activity in intact MCF-7 cells at 0.1  $\mu$ M. EMATE also inhibits the E1-STS enzyme in a time-dependent and concentration-dependent manner, thereby indicating that it acts as an active site-directed inactivator<sup>7,8</sup>.

5

Although EMATE was originally designed for the inhibition of E1-STS, it also inhibits dehydroepiandrosterone sulphotase (DHA-STS), which is an enzyme that is believed to have a pivotal role in regulating the biosynthesis of the oestrogenic steroid androstenediol<sup>8,9</sup>. This is of significance as there is now evidence to suggest that androstenediol may be of even greater importance as a promoter of breast tumour growth<sup>10</sup>.

10

EMATE is also active *in vivo* as almost complete inhibition of rat liver E1-STS (99%) and DHA-STS (99%) activities resulted when it is administered either orally or subcutaneously<sup>11</sup>. In addition, EMATE has been shown to have a memory enhancing effect in rats<sup>14</sup>. Studies in mice have suggested an association between DHA-STS activity and the regulation of part of the immune response. It is thought that this may also occur in humans<sup>15,16</sup>. The bridging O-atom of the sulphamate moiety in EMATE is believed to be important for inhibitory activity. Thus, when the 3-O-atom is replaced by other heteroatoms - as in oestrone-3-N-sulphamate and oestrone-3-S-sulphamate - these analogues are weaker non-time-dependent inactivators<sup>12</sup>.

15

20

Thus, EMATE is a potent steroid sulphotase inhibitor which blocks the hydrolysis of both E1S and DHA-S<sup>29,31</sup>. This inhibitor, therefore, not only blocks the synthesis of oestrone from E1S but also the formation of androstenediol from DHA-S.

25

In addition to oestrone, the other major steroid with oestrogenic properties which is produced by postmenopausal women is androstenediol (see Figure 2).

Androstenediol, although an androgen, can bind to the oestrogen receptor (ER) and can stimulate the growth of ER positive breast cancer cells and the growth of carcinogen-induced mammary tumours in the rat<sup>26,27</sup>. Importantly, in postmenopausal women 90% of the androstenediol produced originates from the androgen dehydroepiandrosterone sulphate (DHA-S) which is secreted in large amounts by the adrenal cortex. DHA-S is converted to DHA by DHA sulphatase, which may be the same as, or different from, the enzyme, oestrone sulphatase, which is responsible for the hydrolysis of E1S<sup>28</sup>.

During the last 10-15 years considerable research has also been carried out to develop potent aromatase inhibitors, some of which are currently undergoing clinical evaluation. However, in three recent reports of postmenopausal women with breast cancer who received aromatase inhibitor therapy, plasma E1S concentrations remained between 400-1000 pg/ml<sup>32-34</sup>.

In summation therefore *in situ* synthesis of oestrogen is thought to make an important contribution to the high levels of oestrogens in tumours and therefore specific inhibitors of oestrogen biosynthesis are of potential value for the treatment of endocrine-dependent tumours.

Moreover, even though oestrogen formation in malignant breast and endometrial tissues *via* the sulphatase pathway makes a major contribution to the high concentration of oestrogens, there are still other enzymatic pathways that contribute to *in vivo* synthesis of oestrogen.

Thus, there is an urgent need to develop new therapies for the treatment of these cancers.

The present invention therefore seeks to overcome one or more of the problems associated with the prior art methods of treating breast and endometrial cancers.

According to a first aspect of the present invention there is provided a sulphamate compound suitable for use as an inhibitor of both oestrone sulphatase activity and aromatase activity.

5 In a highly preferred embodiment, the compound of the present invention is a non-steroidal compound.

10 According to a second aspect of the present invention there is provided a compound having the general formula II wherein F represents a phenolic ring structure (a first ring structure), J represents a third ring structure, I represents a phenolic ring structure (a second ring structure), G is an optional double bond, H is a link joining the second ring structure to the third ring structure, and Y represents a suitable second group; wherein any one of ring structures F, J and I has bound thereto a sulphamate group.

15 According to a third aspect of the present invention there is provided a compound according to the present invention for use as a pharmaceutical.

20 According to a fourth aspect of the present invention there is provided a compound according to the present invention for inhibiting oestrone sulphatase activity and aromatase activity.

25 According to a fifth aspect of the present invention there is provided a pharmaceutical composition comprising a compound according to the present invention; and a pharmaceutically acceptable carrier, excipient or diluent.

According to a sixth aspect of the present invention there is provided the use of a compound according to the present invention in the manufacture of a pharmaceutical for inhibiting oestrone sulphatase activity and aromatase activity.

According to a seventh aspect of the present invention there is provided a process for preparing a compound according to the present invention, the process comprising sulphating a flavone, isoflavone or a flavanone.

- 5 According to an eighth aspect of the present invention there is provided a process for preparing a compound according to the present invention, the process comprising sulphamoylating a flavone, isoflavone or a flavanone.

- 10 In one aspect, therefore, the present invention provides a compound, or a pharmaceutical composition comprising the same, that can affect, such as substantially inhibit, not only the oestrone sulphatase pathway - which pathway converts oestrone to and from oestradiol - but also the aromatase pathway - which pathway converts the androgen precursor androstenedione to oestrone.

- 15 This aspect of the present invention is advantageous because by the administration of one type of compound it is possible to block the synthesis of oestrone from both androstenedione and E1S.

- 20 In addition, the present invention is further advantageous in that it may also be possible to block the formation of androstenediol from DHA-S.

Hence, the present invention provides compounds that have considerable therapeutic advantages, particularly for treating breast and endometrial cancers.

- 25 The compounds of the present invention are different from those disclosed in the prior art because they can act as therapeutic agents that possess both aromatase and steroid sulphatase inhibitory properties.

In a preferred embodiment the compound of the present invention comprises a first ring structure and a sulphamoyl group, which first ring structure may be substituted and/or unsaturated.

5 Preferably the first ring structure is a phenolic ring structure, which phenolic ring may be substituted.

Preferably, the compound of the present invention further comprises a second ring structure, which second ring structure may be substituted and/or unsaturated.

10

Preferably the second ring structure is a phenolic ring structure, which phenolic ring may be substituted.

15

Preferably, the compound of the present invention further comprises a third ring structure which is intermediate the first ring structure and the second ring structure, which third ring structure may be substituted and/or unsaturated.

The present invention will now be described by reference to the Formulae presented in Figures 3-9.

20

In this regard, it is generally preferred that the compound of the present invention has the general formula I wherein A represents the first ring structure, B represents the third ring structure, D represents the second ring structure, C is an optional double bond, E is a link joining the second ring structure to the third ring structure, 25 X represents a suitable first group, and Y represents a suitable second group; wherein any one of ring structures A, B and D is a phenolic ring; and wherein any one of ring structures A, B and D has bound thereto a sulphamate group.

Each of the ring structures can independently comprise from 3 to 20 atoms in the ring, preferably from 4 to 8 atoms in the ring. Preferably, ring A and ring D comprise 6 atoms in the ring.

5 Preferably, the first ring structure and the second ring structure are substituted.

Preferably, any one of ring structures A and D has bound thereto a sulphamate group.

10 Preferably, each of the first ring and the second ring is a homogeneous ring structure - i.e. the ring is made up of the same atoms.

Preferably, each of the first ring and the second ring comprises only carbon atoms in the ring.

15 Preferably, X is C=O.

20 Preferably, the compound of the present invention has the general formula II wherein F represents a phenolic ring structure (the first ring structure), J represents the third ring structure, I represents a phenolic ring structure (the second ring structure), G is an optional double bond, H is a link joining the second ring structure to the third ring structure, and Y represents a suitable second group; wherein any one of ring structures F, J and I has bound thereto a sulphamate group.

25 Preferably, the third ring structure is a heterogeneous ring structure - i.e. different atoms are in the ring.

Preferably, Y is O.

Preferably any one of the ring structures F and I has bound thereto a sulphamate group.

Preferably, link E or link H is a bond.

5

Preferably, the compound of the present invention is a sulphamate of any one of a flavone, an isoflavone or a flavanone.

10

Preferably, the compound of the present invention is any one of a compound of the general formula IV, a compound of the general formula V, or a compound of the general formula VI; wherein  $R_1$ - $R_{12}$  are independently selected from H, OH, a halogen, an amine, an amide, a sulphonamine, a sulphonamide, any other sulphur containing group, a saturated or unsaturated  $C_{1-10}$  alkyl, an aryl group, a saturated or unsaturated  $C_{1-10}$  ether, a saturated or unsaturated  $C_{1-10}$  ester, a phosphorous containing group; and wherein at least one of  $R_1$ - $R_{12}$  is a sulphamate group.

15

20

Preferably, the sulphamate group has the general formula  $OSO_2NR_{13}R_{14}$  wherein  $R_{13}$  and  $R_{14}$  are independently selected from H, OH, a halogen, a saturated or unsaturated  $C_{1-10}$  alkyl, an aryl group, a saturated or unsaturated  $C_{1-10}$  ether, a saturated or unsaturated  $C_{1-10}$  ester.

25

Preferably, the compound of the present invention is any one of a compound of the general formula IV, a compound of the general formula V, or a compound of the general formula VI; wherein  $R_1$ - $R_{12}$  are independently selected from H, OH,  $OSO_2NR_{13}R_{14}$ ,  $O-CH_3$ ; wherein at least one of  $R_1$ - $R_{12}$  is  $OSO_2NR_{13}R_{14}$ , and wherein  $R_{13}$  and  $R_{14}$  are defined as above.

Preferably, each of  $R_{13}$  and  $R_{14}$  is H.

Preferably, the compound of the present invention is a sulphamate of any one of the flavone of formula VII, the isoflavone of formula VIII, or the flavanone of formula IX.

5 Preferably, the compound of the present invention is the sulphamate of any one of formula VII, formula VIII or formula IX.

10 Preferably, the compound of the present invention is a sulphamate of any one of a flavone, an isoflavone or a flavanone; and wherein the sulphamoyl group is on the C4' atom of the flavone, isoflavone or flavanone. The C4' position has been shown in general Formula III according to the present invention.

15 Preferably, the compound of the present invention is a flavonoid or flavanoid sulphamate.

In summation the present invention provides compounds that avoid the need for polytherapy. In this regard, the compounds of the present invention can act as therapeutic agents that possess both aromatase and steroid sulphatase inhibitory properties.

20 Preferably, the compound is hydrolysable by an enzyme having steroid sulphatase (E.C. 3.1.6.2) activity.

25 The present invention will now be described only by way of example.



## COMPOUNDS SYNTHESISED

The following sulphamate derivatives were synthesised from the following parent compounds:

5

PARENT <u>COMPOUND</u>	SULPHAMATE <u>COMPOUND</u>
1	2
3	4
5	6
7	8
9	10

10

wherein

15

1 = 6-hydroxy flavone

2 = flavone-6-sulphamate

3 = 7-hydroxy flavone

4 = flavone-7-sulphamate

20

5 = 5,7-dihydroxy flavone

6 = 5-hydroxy-flavone-7-sulphamate

7 = 5,7-dihydroxy-4'-hydroxy-flavone

8 = 5,7-dihydroxy flavanone-4'-flavanone sulphamate

9 = 5,7-dihydroxy-4'-methoxy-isoflavone

25

10 = 5-hydroxy-4'-methoxy-isoflavone-isoflavone-7-sulphamate

The formulae are presented in Figures 7-9.

## SYNTHESIS

The sulphamate derivatives were prepared essentially as described previously<sup>29</sup>. In this regard, solutions of the appropriate flavone, isoflavone or flavanone were treated in anhydrous DMF with sodium hydride (1 equiv) at 0°C (under N<sub>2</sub>). Sulphamoyl chloride (ca 1.5 equiv) was then added, and after the mixture was warmed to room temperature overnight and the reaction quenched, the crude product, after work up for each flavone, isoflavone or flavanone, was purified by flash chromatography and recrystallization. All compounds were fully characterised by spectroscopic and combustion analysis.

## ASSAY OF INHIBITION OF SULPHATASE AND AROMATASE ACTIVITIES

Sulphatase inhibition was assessed using placental microsome (100,000 g) preparations or intact MCF-7 breast cancer cells as described previously<sup>29,30</sup>. Placental microsomes were incubated with <sup>3</sup>H E1S, adjusted to 20 μM with unlabelled substrate, in the absence or presence of inhibitor.

Placental microsomes were also used to assess the aromatase inhibitory properties of the flavanoid sulphamates using a tritiated water release assay<sup>37</sup>. Further placental microsomes (200 μl) were incubated with [1β-<sup>3</sup>H] androstenedione, 60 nM and 1 mM NADPH in the absence or presence of inhibitor.

## INHIBITION OF SULPHATASE AND AROMATASE ACTIVITIES

Inhibition of oestrone sulphatase and aromatase activities in placental microsomes by the flavanoid sulphamate derivatives is shown in the Table below.

	CONCENTRATION	% INHIBITION	% INHIBITION
COMPOUND			
	$\mu\text{M}$	Sulphatase	Aromatase
Flavone-6-sulphamate	1	26.8	1
	10	89.5	6.5
Flavone-7-sulphamate	1	-	55
	10	-	86
	50	56.3	
	100	75.3	
5-hydroxy flavone-7-sulphamate	1	8	5
	10	21	76
5,7-dihydroxy flavanone 4'-sulphamate	0.1	30.4	Not tested
	1	79.1	Not tested
	10	98.1	Not tested
5-hydroxy-4'-methoxy-isoflavone-7-sulphamate	1	1	2
	10	50.6	5

From the results, it can be seen that potent inhibition of sulphatase and aromatase activities was detected. For sulphatase inhibition this ranged from 21 % at 10  $\mu\text{M}$  by 5-hydroxy flavone-7-sulphamate, to 98% by 5,7-dehydroxy flavanone-4'-sulphamate at 10  $\mu\text{M}$ . Potent aromatase inhibition was also achieved ranging from 6.5% by flavone-6-sulphamate at 10  $\mu\text{M}$  to 86% by flavone-7-sulphamate at 10  $\mu\text{M}$ .

Other modifications of the present invention will be apparent to those skilled in the art.

## REFERENCES

- 5 (1) Santner, S. J.; Feil, P. D.; Santen, R. J. *In situ* oestrogen production via the oestrone sulphatase pathway in breast tumors: relative importance vs. the aromatase pathway. *J. Clin. Endocrinol. Metab.* **1984**, *59*, 29-33.
- 10 (2) Yamamoto, T.; Kitawaki, J.; Urabe, M.; Honjo, H.; Tamura, T.; Noguchi, T.; Okada, H.; Sasaki, H.; Tada, A.; Terashima, Y.; Nakamura, J.; Yoshihama, M. Oestrogen productivity of endometrium and endometrial cancer tissue - influence of aromatase on proliferation of endometrial cancer cells. *J. Steroid Biochem. Mol. Biol.* **1993**, *44*, 463-468.
- 15 (3) Santen, R. J.; Santner, S. J.; Davis, B.; Veldhuis, J.; Samojilik, E.; Ruby, E. Aminogluthethimide inhibits extraglandular oestrogen production in post-menopausal women with breast carcinoma. *J. Clin. Endocrinol. Metab.* **1978**, *47*, 1257-1265.
- 20 (4) Reed, M. J.; Lai, L. C.; Owen, A. M.; Singh, A.; Coldham, N. G.; Purohit, A.; Ghilchik, M. W.; Shaikh, N. A.; James, V. H. T. Effect of treatment with 4-hydroxy-androstenedione on the peripheral conversion of androstenedione to oestrone and *in vitro* tumour aromatase activity in postmenopausal women with breast cancer. *Cancer Res.* **1990**, *50*, 193-196.
- 25 (5) Ruder, H. J.; Loriaux, D. L.; Lipsett, M. B. Oestrone sulphate: production rate and metabolism in man. *J. Clin. Invest.* **1972**, *51*, 1020-1023.
- (6) James, V. H. T.; McNeill, J. M.; Lai, L. C.; Newton, C. J.; Ghilchik, M. W.; Reed, M. J. Aromatase activity in normal breast and breast tumor tissues: *in vivo* and *in vitro* studies. *Steroids* **1987**, *50*, 269-279.

- (7) Howarth, N. M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Oestrone sulphamates: potent inhibitors of oestrone sulphatase with therapeutic potential. *J. Med. Chem.* 1994, 37, 219-221.
- 5 (8) Purohit, A.; Williams, G. J.; Howarth, N. M.; Potter, B. V. L.; Reed, M. J. Inactivation of steroid sulphatase by an active site-directed inhibitor, oestrone-3-*O*-sulphamate. *Biochemistry* 1995, 34, 11508-11514.
- 10 (9) Purohit, A.; Dauvois, S.; Parker, M. G.; Potter, B. V. L.; Williams, G. J.; Reed, M. J. The hydrolysis of oestrone sulphate and dehydroepiandrosterone sulphate by human steroid sulphatase expressed in transfected COS-1 cells. *J. Steroid Biochem. Mol. Biol.* 1994, 50, 101-104.
- 15 (10) Dauvois, S.; Labrie, F. Androstenedione and androst-5-ene-3 $\beta$ ,17 $\beta$ -diol stimulate DMBA-induced rat mammary tumours - role of aromatase. *Breast Cancer Res. Treat.* 1989, 13, 61-69.
- 20 (11) Purohit, A.; Williams, G. J.; Roberts, C. J.; Potter, B. V. L.; Reed, M. J. *In vivo* inhibition of oestrone sulphatase and dehydroepiandrosterone sulphatase by oestrone-3-*O*-sulphamate. *Int. J. Cancer* 1995, 63, 106-111.
- 25 (12) Woo, L. W. L.; Lightowler, M.; Purohit, A.; Reed, M. J.; Potter, B. V. L. Heteroatom-substituted analogues of the active-site directed inhibitor oestra-1,3,5(10)-trien-17-one-3-sulphamate inhibit oestrone sulphatase by a different mechanism. *J. Steroid Biochem. Mol. Biol.* 1996 (in press).
- (13) Elger, W.; Schwarz, S.; Hedden, A.; Reddersen, G.; Schneider, B. Sulphamates of various oestrogens - prodrugs with increased systemic and reduced hepatic oestrogenicity at oral application. *J. Steroid Biochem. Mol. Biol.* 1995, 55,

395-403.

- 5 (14) Li, P. K.; Rhodes, M. E.; Jagannathan, S.; Johnson, D. A. Memory enhancement mediated by the steroid sulphatase inhibitor oestrone 3-*O*-sulphamate. *J. Endocrinol.* 1995, 144, Abstr. P155.

- 10 (15) Daynes, R. A.; Araneo, B. A.; Dowell, T. A.; Huang, K.; Dudley, D. Regulation of murine lymphokine production *in vivo*. 3. The lymphoid tissue micro-environment exerts regulatory influences over T-helper cell function. *J. Exp. Med.* 1990, 171, 979-996.

- 15 (16) Rook, G. A. W.; Hernandez-Pando, R.; Lightman, S. Hormones, peripherally activated prohormones and regulation of the TH1/TH2 balance. *Immunol. Today* 1994, 15, 301-303.

- (21) James & Reed (1980) *Prog Cancer Res Ther* 14: 471-487.

- (22) James *et al* (1987) *Steroids* 50: 269-279.

- 20 (23) Reed *et al* (1994) *Drugs for the Future* 19: 673-680.

- (24) Santner *et al* (1984) *J Clin Endocr Metab* 59: 29-33.

- 25 (25) Yamamoto *et al* (1993) *J Steroid Biochem Molec Biol* 44: 463-468.

- (26) Poulin & Labrie (1986) *Cancer Res* 46: 4933-4937.

- (27) Dauvois & Labrie (1989) *Breast Cancer Res Treat* 13: 61-69.

(28) Purohit *et al* (1994) J Steroid Biochem Mol Biol **50**: 101-104.

(29) Howarth *et al* (1994) J Med Chem **37**: 219-221.

5 (30) Purohit *et al* (1995) Biochemistry **34**: 11508-11514.

(31) Purohit *et al* (1995) Int J Cancer **62**: 106-111.

(32) Svenstrup *et al* (1994) Eur J Cancer **30A**: 1254-1258.

10

(33) Johnston *et al* (1994) Cancer Res **54**: 5875-5881.

(34) Dowsett *et al* (1994) Eur J Cancer **30A**: 1453-1458.

15 (35) Kellis *et al* (1986) Biochem Pharmacol **35**: 2887-2891.

(36) Campbell & Kurzer (1993) J Steroid Biochem Molec Biol **46**: 381-388.

(37) Newton *et al* (1986) J Steroid Biochem **24**: 1033-1039.

20

## CLAIMS

1. A sulphamate compound suitable for use as an inhibitor of both oestrone sulphatase activity and aromatase activity.
- 5 2. A compound according to claim 1 wherein the compound comprises a first ring structure and a sulphamoyl group, which first ring structure may be substituted and/or unsaturated.
- 10 3. A compound according to claim 2 wherein the first ring structure is a phenolic ring structure, which phenolic ring may be substituted.
- 15 4. A compound according to any one of claims 1 to 3 wherein the compound further comprises a second ring structure, which second ring structure may be substituted and/or unsaturated.
5. A compound according to claim 4 wherein the second ring structure is a phenolic ring structure, which phenolic ring may be substituted.
- 20 6. A compound according to any one of claims 1 to 5 wherein the compound further comprises a third ring structure which is intermediate the first ring structure and the second ring structure, which third ring structure may be substituted and/or unsaturated.
- 25 7. A compound according to claim 6 wherein the compound has the general formula I; wherein A represents the first ring structure, B represents the third ring structure, D represents the second ring structure, C is an optional double bond, E is a link joining the second ring structure to the third ring structure, X represents a suitable first group, and Y represents a suitable second group; wherein any one of ring



structures A, B and D is a phenolic ring; and wherein any one of ring structures A, B and D has bound thereto a sulphamate group.

5 8. A compound according to claim 7 wherein the compound has the general formula II wherein F represents a phenolic ring structure (the first ring structure), J represents the third ring structure, I represents a phenolic ring structure (the second ring structure), G is an optional double bond, H is a link joining the second ring structure to the third ring structure, and Y represents a suitable second group; wherein any one of ring structures F, J and I has bound thereto a sulphamate group.

10

9. A compound having the general formula II wherein F represents a phenolic ring structure (a first ring structure), J represents a third ring structure, I represents a phenolic ring structure (a second ring structure), G is an optional double bond, H is a link joining the second ring structure to the third ring structure, and Y represents  
15 a suitable second group; wherein any one of ring structures F, J and I has bound thereto a sulphamate group.

20

10. A compound according to any one of claims 7 to 9 wherein the first ring structure and the second ring structure are substituted.

11. A compound according to any one of claims 7 to 10 wherein any one of ring structures A or F and D or I has bound thereto a sulphamate group.

25

12. A compound according to any one of claims 7 to 11 wherein the third ring structure is a heterogeneous ring structure.

13. A compound according to any one of claims 7 to 12 wherein X is C=O.

14. A compound according to any one of claims 7 to 13 wherein Y is O.

15. A compound according to any one of the preceding claims wherein the compound of the present invention is a sulphamate of any one of a flavone, an isoflavone or a flavanone.

5 16. A compound according to claim 15 wherein the compound is any one of: a compound of the general formula IV, a compound of the general formula V or a compound of the general formula VI; wherein  $R_1$ - $R_{12}$  are independently selected from H, OH, a halogen, an amine, an amide, a sulphonamine, a sulphonamide, any other sulphur containing group, a saturated or unsaturated  $C_{1-10}$  alkyl, an aryl group, a  
10 saturated or unsaturated  $C_{1-10}$  ether, a saturated or unsaturated  $C_{1-10}$  ester, a phosphorous containing group; and wherein at least one of  $R_1$ - $R_{12}$  is a sulphamate group.

15 17. A compound according to any one of the preceding claims wherein the sulphamate group has the general formula  $QSO_2NR_{13}R_{14}$  wherein  $R_{13}$  and  $R_{14}$  are independently selected from H, OH, a halogen, a saturated or unsaturated  $C_{1-10}$  alkyl, an aryl group, a saturated or unsaturated  $C_{1-10}$  ether, a saturated or unsaturated  $C_{1-10}$  ester

20 18. A compound according to any one of the preceding claims wherein the compound is any one of a compound of the general formula IV, a compound of the general formula V or a compound of the general formula VI; wherein  $R_1$ - $R_{12}$  are independently selected from H, OH,  $OSO_2NR_{13}R_{14}$ ,  $O-CH_3$ ; wherein at least one of  $R_1$ - $R_{12}$  is  $OSO_2NR_{13}R_{14}$ , and wherein  $R_{13}$  and  $R_{14}$  are defined in claim 17.

25 19. A compound according to claim 16 or claim 17 wherein  $R_{13}$  and  $R_{14}$  are H.

30 20. A compound according to any one of the preceding claims wherein the compound is a sulphamate of any one of the flavone of formula VII, the isoflavone of formula VIII or the flavanone of formula IX.

21. A compound according to any one of the preceding claims wherein the compound is the sulphamate of any one of formula VII, formula VIII or formula IX.

22. A compound according to any one of the preceding claims wherein the compound is a sulphamate of any one of a flavone, an isoflavone or a flavanone; and wherein the sulphamoyl group is on the C4' atom of the flavone, isoflavone or flavanone.

23. A compound according to any one of the preceding claims wherein the compound is a flavanoid sulphamate.

24. A compound according to any one of the preceding claims for use as a pharmaceutical.

25. A compound according to any one of claims 1 to 23 for inhibiting oestrone sulphatase activity and aromatase activity.

26. A pharmaceutical composition comprising a compound according to any one of claims 1 to 23; and a pharmaceutically acceptable carrier, excipient or diluent.

27. Use of a compound according to any one of claims 1 to 23 in the manufacture of a pharmaceutical for inhibiting oestrone sulphatase activity and aromatase activity.

28. A process for preparing a compound according to any one of claims 1 to 23, the process comprising sulphating a flavone, isoflavone or a flavanone.

29. A process for preparing a compound according to any one of claims 1 to 23, the process comprising sulphamoylating a flavone, isoflavone or a flavanone.

30. A compound substantially as described herein.

31. A process of preparing a compound substantially as described herein.

## ABSTRACT

A COMPOUND


5

A sulphamate compound is described. The compound is suitable for use as an inhibitor of both oestrone sulphatase activity and aromatase activity. A preferred compound has the general formula II wherein F represents a phenolic ring structure (the first ring structure), J represents the third ring structure, I represents a phenolic ring structure (the second ring structure), G is an optional double bond, H is a link joining the second ring structure to the third ring structure, and Y represents a suitable second group; wherein any one of ring structures F, J and I has bound thereto a sulphamate group.

10  
15Fig 3b

Fig 1


1/5



KEY ENZYMES IN STEROIDOGENESIS:-

1. CHOLESTEROL 2-OXIDASE
2. 17 $\beta$ -HSD
3. 17 $\beta$ -HSD
4. 17 $\beta$ -HSD
5. 17 $\beta$ -HSD
6. 5 $\alpha$ -REDUCTASE
7. 17 $\beta$ -HSD
8. 17 $\beta$ -HSD
9. 17 $\beta$ -HSD
10. 17 $\beta$ -HSD

# Origin of Oestrogenic Steroids in Postmenopausal Women



ER = Oestrogen Receptor, DHA / -S = Dehydroepiandrosterone / -Sulphate,  
Adiol = Androstenediol, E1-STS = Oestrone Sulphatase, DHA -STS =  
DHA-sulphatase, Adiol-STS = Adiol-Sulphatase, 17B-HSD = Oestradiol 17B-  
hydroxysteroid dehydrogenase

Fig 3a

3/5




Fig 3b




Fig 3c






Fig 4

4/5

IV




Fig 5

V






Fig 6

VI



FLAVONES


Fig 7

VII

	<u>R<sub>1</sub></u>	<u>R<sub>2</sub></u>	<u>R<sub>3</sub></u>	<u>R<sub>4</sub></u>
1	H	OH	H	H
2	H	OSO <sub>2</sub> NH <sub>2</sub>	H	H
3	H	H	OH	H
4	H	H	OSO <sub>2</sub> NH <sub>2</sub>	H
5	OH	H	OH	H
6	OH	H	OSO <sub>2</sub> NH <sub>2</sub>	H

ISOFLAVONES


Fig 8

VIII

	<u>R<sub>1</sub></u>	<u>R<sub>2</sub></u>	<u>R<sub>3</sub></u>	<u>R<sub>4</sub></u>
9	OH	H	OH	OCH <sub>3</sub>
10	OH	H	OSO <sub>2</sub> NH <sub>2</sub>	OCH <sub>3</sub>

FLAVANONES

Fig 9


IX

	<u>R<sub>1</sub></u>	<u>R<sub>2</sub></u>	<u>R<sub>3</sub></u>	<u>R<sub>4</sub></u>
7	OH	H	OH	OH
8	OH	H	OH	OSO <sub>2</sub> NH <sub>2</sub>

① 97/00600

② 5 3.96

③ L Young & Co



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**